Clinical Trial Update: Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating ME-609 in combination with acyclovir for treatment of herpes labialis in immunocompromised patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Labialis

Drugs mentioned

• ACYCLOVIR (Acyclovir)
• ME-609

Snippet

Sponsor: Medivir | Conditions: Herpes Labialis | Phase 3 | Status: COMPLETED